Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.22 – $19.87
31% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $150.0K | $0 | $0 | $0 | $0 | $420.0K | $43.0K | $747.0K |
| Cost of revenue | $4.3M | $0 | $20.0K | $43.0K | $32.0K | $31.0K | $6.0K | $609.0K |
| Gross profit | −$4.2M | −$20.0K | −$20.0K | −$43.0K | −$32.0K | $420.0K | $43.0K | $138.0K |
| Gross margin | -2784.7% | — | — | — | — | 100.0% | 100.0% | 18.5% |
| R&D | $4.3M | $4.7M | $4.8M | $14.9M | $20.3M | $19.2M | $6.7M | $848.0K |
| Operating income | −$9.5M | −$9.7M | −$10.6M | −$22.9M | −$27.7M | −$25.5M | −$12.0M | −$8.4M |
| EBITDA | −$9.5M | −$9.7M | −$10.6M | −$22.7M | −$27.6M | −$25.4M | −$12.0M | $5.0K |
| Net income | −$7.3M | −$7.8M | −$8.4M | −$18.9M | −$21.2M | −$22.6M | −$11.2M | −$3.0M |
| Net margin | -4858.7% | — | — | — | — | -5370.2% | -26074.4% | -401.3% |
| EPS (diluted) | -12.46 | -9.64 | -12.73 | -32.10 | -28.50 | -28.67 | -1.36 | -6.45 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $100000 | $-268.80 | $-268.80–$-268.80 | 1 |
| 2027 | $81M | $880.80 | $880.80–$880.80 | 1 |
| 2028 | $118M | $1317.60 | $1317.60–$1317.60 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds CYCC.
No tracked institution reports a position in CYCC as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-04-29 | $0.1500 | 2025-05-01 |
| Execution date | Ratio |
|---|---|
| 2023-12-18 | 1-for-15reverse |
| 2020-04-15 | 1-for-20reverse |
| 2016-05-31 | 1-for-12reverse |
| 2012-08-27 | 1-for-7reverse |
No one on the platform has traded CYCC yet.
| $12M |
| — |
| IMVIFIMV Inc. | $0.00 | +0.00% | $23423 | — |
| KRROKorro Bio, Inc. | $13.20 | +3.90% | $131M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at NaN× sales vs its 16.6× historical median P/S.
Fair value ≈ $-0.21 · price $6.37 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.